No Data
Express News | [Change Report] Sekisui House reported a decrease in the shareholding ratio of Daihatsu Diesel (6023.JP) to 6.28%.
<Today's Materials and Key Stocks> Container ship ONE is set to build over 40 new vessels - mark related stocks.
It has been reported that the container shipping company Ocean Network Express (ONE), funded by three major shipping companies, plans to invest $25 billion (approximately 3.7 trillion yen) by the fiscal year 2030. They aim to build over 40 new vessels by fiscal year 2028 and expand their operating scale by 30% compared to August 2024. Related stocks include shipbuilders Mitsubishi Heavy Industries <7011.T>, IHI <7013.T>, Namura Shipbuilding <7014.T>, and Utsunomiya Shipbuilding <7018.T>, as well as engine manufacturers Mitsui E&S <7003.T> and J-E.
Stocks that moved the day before part 2 Seer Inc, Seer Inc, Intest Corp, ETC.
Stock Name <Code> Closing Price on the 29th ⇒ Day-on-Day Change Unitika <3103> 151 -6 Short-term funds are selling off due to a sense of rebound completion. KLab <3656> 154 -8 A sense of completion may also be present in the rapid rebound. Japan Glass <5202> 383 -15 Recently, there was a rise due to a review of European production systems. Koei Tecmo <3635> 1931.5 -58.5 Iwai Cosmo Securities downgraded its investment determination. Disco <6146> 45310 +80
Daihatsu Diesel Mfg.'s Attributable Profit Surges 63% in Nine Months to December 2024
Spot information on individual stocks (1)
Intest Corp <6721.T> surges. Released the wafer acceptance test inspection device "WTS-511". Daihatsu <6023.T> hits a record high since last year. Upgraded consolidated earnings and Dividends forecast for the current March period. Conducting a tender offer for shares with a maximum of approximately 6.28 million shares (19.72% of issued shares). Lact J <3139.T> sees a significant increase. UBS upgraded the rating from "neutral" to "Buy". Nippon Gas <8174.T> remains steady.
WinTest, Impress, Tokokata ETC.
＜4208＞ UBE 2329.5 +1.5 showed a slight rebound. On the previous day, a downward revision of the performance for the fiscal year ending in March 2025 was announced, with operating profit revised down from the previous estimate of 27 billion yen to 16 billion yen. The market estimate was around 24 billion yen, which was seen as a more significant downturn than expected. The sluggish sales of caprolactam and other products were behind this. Additionally, due to special losses from production stoppages and impairment losses, the net profit was revised down from a surplus of 29.5 billion yen to a deficit of 17.5 billion yen. The progress of such structural reforms is positive.